CBR3 and breast cancer: Interestingly, a cross-sectional observational study of anthracycline-induced cardiomyopathy in a cohort of women with breast cancer found the CBR3 V244M AA genotype more often in patients with systolic dysfunction than in cases with normal LVEF > 55% [29].